Chronic News and Research

RSS

Shire acquires rights to develop and market Resolor in the U.S.

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the agreement have not been disclosed.

10 Jan 2012

New evidence on heading and risk of brain injury in soccer

Could heading the ball in soccer lead to degenerative brain disease, like that seen in athletes in other sports? That's the question addressed by a review in the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

10 Jan 2012

Experts want young athletes to become more aware of warning signs of concussion

Concussion in youth sports is a serious issue, as young athletes' brains are more susceptible to injuries. These injuries can become more serious as players suffer repeated incidents. Sports related concussions have generated a significant amount of attention, with numerous well-known school and professional athletes out of the game due to concussion.

10 Jan 2012

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Lixte Biotechnology Holdings announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.

9 Jan 2012

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Oxygen Biotherapeutics, Inc. has announced that enrollment for the company’s first dermatological study will begin later this month at St. John’s Medical College Hospital in Bangalore, India. The company received formal approval from the hospital’s Ethics Review Board in December. This study is the first of a series of trials scheduled for 2012 to explore the efficacy of Dermacyte to treat a variety of dermatological conditions, such as allergic contact dermatitis, psoriasis and acne.

9 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

CCPR completes new specialty behavioral health provider network

Comprehensive Care Corporation, which provides behavioral health, substance abuse and at-risk psychotropic pharmacy management services for managed care companies throughout the U.S. and Puerto Rico, is pleased to announce that CompCare de Puerto Rico (CCPR) has completed its build out of a fully contracted and credentialed specialty behavioral health provider network to better serve its clients and insured Medicare and dual-eligible members across the Island of Puerto Rico.

9 Jan 2012

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.

9 Jan 2012

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Bristol-Myers Squibb Company and Inhibitex, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.

8 Jan 2012

Americans cutting costs by skipping prescription drugs

A Consumer Reports survey revealed that more Americans are ignoring their doctor’s advice and skipping prescription drugs or medical procedures to save money in 2011 than a year earlier.

8 Jan 2012

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories - public and private financings, fast growing companies, acquisitions and SBIR grants - reflecting a broad range of activity.

From Medtronic 7 Jan 2012

Cardinal Health launches infusion room management tool for community rheumatologists

Cardinal Health Specialty Solutions today launched InfusaTrack, a Web-based infusion room management tool that makes it easier for community rheumatology practices to offer in-office infusion therapy services to patients.

7 Jan 2012

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

AccuGenomics announced today that it will be attending the upcoming OneMedForum at the Sir Francis Drake hotel in San Francisco on January 9-12, coinciding with the JP Morgan Global Healthcare Conference.

7 Jan 2012

Prospective surveillance model can reduce treatment costs for breast cancer-related lymphedema

Early diagnosis and treatment of breast cancer-related lymphedema by a physical therapist can significantly reduce costs and the need for intensive rehabilitation, according to an article published in the January issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association.

7 Jan 2012

Pearl Therapeutics completes two PT003 Phase 2b clinical studies on COPD

Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003, the Company's investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD.

7 Jan 2012

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Savient Pharmaceuticals, Inc. today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA (pegloticase) became available on January 1, 2012.

7 Jan 2012

KAI commences enrollment in KAI-4169 second Phase 2 study for CKD-MBD

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.

6 Jan 2012

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

6 Jan 2012

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioDelivery Sciences International, Inc. today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.

6 Jan 2012

Chronic News and Research

Shire acquires rights to develop and market Resolor in the U.S.

New evidence on heading and risk of brain injury in soccer

Experts want young athletes to become more aware of warning signs of concussion

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Oxygen Biotherapeutics to commence study to determine efficacy of Dermacyte in relieving Histamine induced pruritus

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

CCPR completes new specialty behavioral health provider network

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Americans cutting costs by skipping prescription drugs

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Cardinal Health launches infusion room management tool for community rheumatologists

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

Prospective surveillance model can reduce treatment costs for breast cancer-related lymphedema

Pearl Therapeutics completes two PT003 Phase 2b clinical studies on COPD

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

KAI commences enrollment in KAI-4169 second Phase 2 study for CKD-MBD

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News